Recombinant vaccines for COVID-19
Open accessAbstract
SARS-CoV-2, the causative agent of COVID-19, has imposed a major public health threat, which needs effective therapeutics and vaccination strategies. Several potential candidate vaccines being rapidly developed are in clinical evaluation. Considering the crucial role of SARS-CoV-2 spike (S) glycoprotein in virus attachment, entry, and induction of neutralizing antibodies, S protein is being widely used as a target for vaccine development. Based on advances in techniques for vaccine design, inactivated, live-vectored, nucleic acid, and recombinant COVID-19 vaccines are being developed and tested for their efficacy. Phase3 clinical trials are underway or will soon begin for several of these vaccines. Assuming that clinical efficacy is shown for one or more vaccines, safety is a major aspect to be considered before deploying such vaccines to the public. The current review focuses on the recent advances in recombinant COVID-19 vaccine research and development and associated issues.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Studies have found that the S protein prefusion conformation induces better immunogenicity and can be considered an ideal target antigen.
“Studies have found that the S protein prefusion conformation induces better immunogenicity and can be therefore considered an ideal target antigen.237”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [237]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575 · see citing works
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907 · see citing works
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works
Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., Neuman, B. W., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,436 · see citing works
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak
Rothan, H. A., & Byrareddy, S. N. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102433 · Cited by 5,840 · see citing works
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069 · see citing works
Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins
Lam, T. T., Jia, N., Zhang, Y.-W., Shum, M. H.-H., Jiang, J.-F., Zhu, H., Tong, Y., Shi, Y., Ni, X.-B., Liao, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2169-0 · Cited by 1,877 · see citing works
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654 · see citing works
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537 · see citing works
Development of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434 · see citing works
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works
Liu, C., Zhou, Q. A., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S. R., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,304 · see citing works
The Novel Coronavirus Originating in Wuhan, China
Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210 · see citing works
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120 · see citing works
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997 · see citing works
Cross‐species transmission of the newly identified coronavirus 2019‐nCoV
Ji, W., Wang, W., Zhao, X., Zai, J., & Li, X. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25682 · Cited by 942 · see citing works
Song, W., Gui, M., Wang, X., & Xiang, Y. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007236 · Cited by 842 · see citing works
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688 · see citing works
Xu, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020) · Viruses · doi:10.3390/v12020244 · Cited by 682 · see citing works
Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y. S., Singh, K. P., & Chaicumpa, W. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1735227 · Cited by 622 · see citing works
Self-citationImmunogenicity of a DNA vaccine candidate for COVID-19
Smith, T. R. F., Patel, A., Ramos, S., Elwood, D., Zhu, X., Yan, J., Gary, E. N., Walker, S. N., Schultheis, K., Purwar, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16505-0 · Cited by 601 · see citing works
Kushnir, N., Streatfield, S. J., & Yusibov, V. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 590 · see citing works
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Mohsen, M. O., Zha, L., Cabral‐Miranda, G., & Bachmann, M. F. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.014 · Cited by 560 · see citing works
Developments in Viral Vector-Based Vaccines
Ura, T., Okuda, K., & Shimada, M. (2014) · Vaccines · doi:10.3390/vaccines2030624 · Cited by 437 · see citing works
Is COVID-19 receiving ADE from other coronaviruses?
Tetro, J. A. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.02.006 · Cited by 437 · see citing works
Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS
Drexler, J. F., Corman, V. M., & Drosten, C. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.10.013 · Cited by 406 · see citing works
Kim, E., Erdös, G., Huang, S., Kenniston, T. W., Balmert, S. C., Carey, C. D., Raj, V. S., Epperly, M. W., Klimstra, W. B., Haagmans, B. L., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102743 · Cited by 405 · see citing works
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic
Lythgoe, M. P., & Middleton, P. K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.03.006 · Cited by 380 · see citing works
Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344 · see citing works
The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
Shang, W., Yang, Y., Rao, Y., & Rao, X. (2020) · npj Vaccines · doi:10.1038/s41541-020-0170-0 · Cited by 275 · see citing works
Kumar, S., Maurya, V. K., Prasad, A. K., Bhatt, M. L. B., & Saxena, S. K. (2020) · VirusDisease · doi:10.1007/s13337-020-00571-5 · Cited by 228 · see citing works
Self-citationAbdelmageed, M. I., Abdelmoneim, A. H., Mustafa, M. I., Elfadol, N. M., Murshed, N. S., Shantier, S. W., & Makhawi, A. M. (2020) · BioMed Research International · doi:10.1155/2020/2683286 · Cited by 207 · see citing works
Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees
Jiang, S. (2020) · Nature · doi:10.1038/d41586-020-00751-9 · Cited by 174 · cited 1× · see citing works
“Therefore, the corresponding regulatory authorities should evaluate the safety profile of potential SARS-CoV -2 vaccines using an array of virus strains and a variety of animal models.(48)”
BackgroundSpruth, M., Kistner, O., Savidis-Dacho, H., Hitter, E., Crowe, B. A., Gerenčer, M., Brühl, P., Grillberger, L., Reiter, M., Tauer, C., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.055 · Cited by 121 · see citing works
What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?
Rosales‐Mendoza, S., Márquez-Escobar, V. A., González‐Ortega, O., Nieto‐Gómez, R., & Arévalo-Villalobos, J. I. (2020) · Vaccines · doi:10.3390/vaccines8020183 · Cited by 103 · see citing works
Zhou, J., Wang, W., Zhong, Q., Hou, W., Yang, Z., Xiao, S., Runqing, Z., Tang, Z., Wang, Y., Xian, Q., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.11.075 · Cited by 78 · see citing works
Global Trends in Epidemiology of Coronavirus Disease 2019 (COVID-19)
Srivastava, N., Baxi, P., Ratho, R. K., & Saxena, S. K. (2020) · Medical virology · doi:10.1007/978-981-15-4814-7_2 · Cited by 60 · see citing works
Self-citationPrevention and Control Strategies for SARS-CoV-2 Infection
Srivastava, N., & Saxena, S. K. (2020) · Medical virology · doi:10.1007/978-981-15-4814-7_11 · Cited by 33 · see citing works
Self-citationWang, J., & Zand, M. S. (2020) · Journal of Clinical and Translational Science · doi:10.1017/cts.2020.39 · Cited by 26 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- [27]Pharmaceutical Business Review. 2020 Apr 18. [Accessed 2020 Aug 31]. https://www.pharmaceutical-business-review.com/news/sinovac-biotech-covid-19-vaccine-trial/.
- [32]Oncosec. 2020 Apr 18. [Accessed 2020 Aug 31]. https://ir.oncosec.com/press-releases/detail/2042/oncosec-collaborates-with-providence-cancer-institute-to.
- [35]Tazehkand MN, Hajipour O. Evaluating the vaccine potential of a tetravalent fusion protein against coronavirus (COVID-19). J Vaccines Vaccin. 2020; 11: 411.
- [36]Glaxo. GlaxoSmithKline press release on 2/24/20; 2020 Apr 11. [Accessed 2020 Aug 31]. https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-researchcollaboration-to-evaluate-coronavirus-covid-19-vaccine-candidatewith-pandemic-adjuvant-system.
- [38]Generex. press release on 2/27/2020; 2020. [Accessed 2020 Aug 31]. https://storage.googleapis.com/wzukusers/user26831283/documents/5e57ed391b286sVf68Kq/PR_Generex_Coronavirus_Update_2_27_2020.pdf.
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460 · see citing works
Choudhary, S., Malik, Y. S., & Tomar, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01664 · Cited by 228 · see citing works
Maleki, A., Look-Why, S., Manhapra, A., & Foster, C. S. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i3.9443 · Cited by 92 · see citing works
Tracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 76 · see citing works
Self-citationCombatting Salmonella: a focus on antimicrobial resistance and the need for effective vaccination
Nazir, J., Manzoor, T., Saleem, A., Gani, U., Saleem, S., Khan, S. A., Haq, Z., Jha, P., & Ahmad, S. M. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10478-5 · Cited by 69 · see citing works
Mörz, M. (2022) · Vaccines · doi:10.3390/vaccines10101651 · Cited by 65 · see citing works
Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine
Özdemir, İ. H., Özlek, B., Özen, M. B., Gündüz, R., & Bayturan, Ö. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.04.018 · Cited by 53 · see citing works
Banihashemi, S. R., Es‐haghi, A., Mehrabadi, M. H. F., Noofeli, M., Mokarram, A. R., Ranjbar, A., Salman, Μ. D., Hajimoradi, M., Razaz, S. H., Taghdiri, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836745 · Cited by 48 · see citing works
Anti-vaccination movements in the world and in Brazil
de Oliveira, I. S., Cardoso, L. S., Ferreira, I. G., Alexandre-Silva, G. M., Jacob, B. D. C. D. S., Cerni, F. A., Monteiro, W. M., Zottich, U., & Pucca, M. B. (2022) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0592-2021 · Cited by 46 · see citing works
Mücke, V. T., Knop, V., Mücke, M. M., Ochsendorf, F. R., & Zeuzem, S. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06655-x · Cited by 41 · see citing works
Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity
Zhou, W., Xu, C., Wang, P., Anashkina, A. A., & Jiang, Q. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab375 · Cited by 41 · see citing works
A behavioral economics perspective on the COVID-19 vaccine amid public mistrust
Saleska, J. L., & Choi, K. R. (2021) · Translational Behavioral Medicine · doi:10.1093/tbm/ibaa147 · Cited by 38 · see citing works
Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response
Carascal, M. B., Pavon, R. D. N., & Rivera, W. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878943 · Cited by 34 · see citing works
Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges
Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 34 · see citing works
Bezbaruah, R., Borah, P., Kakoti, B. B., Al‐Shar’i, N. A., Chandrasekaran, B., Jaradat, D. M. M., Al‐Zeer, M. A., & Abu-Romman, S. M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.635337 · Cited by 30 · see citing works
Aileni, M., Rohela, G. K., Jogam, P., Soujanya, S., & Zhang, B. (2022) · Cells · doi:10.3390/cells11071182 · Cited by 29 · see citing works
Haq, I. U., Krukiewicz, K., Yahya, G., Haq, M. U., Maryam, S., Mosbah, R., Saber, S., & Alrouji, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021536 · Cited by 25 · see citing works
Parental awareness and utilization of meningococcal serogroup B vaccines in the United States
Srivastava, A. K., Dempsey, A. F., Galitsky, A., Fahimi, M., & Huang, L. (2020) · BMC Public Health · doi:10.1186/s12889-020-09181-8 · Cited by 25 · see citing works
Therapeutic approaches for SARS-CoV-2 infection
Gupta, A., Pradhan, A., Maurya, V. K., Kumar, S., Theengh, A., Puri, B., & Saxena, S. K. (2021) · Methods · doi:10.1016/j.ymeth.2021.04.026 · Cited by 23 · see citing works
Self-citationStructural and molecular perspectives of SARS-CoV-2
Kumar, S., & Saxena, S. K. (2021) · Methods · doi:10.1016/j.ymeth.2021.03.007 · Cited by 21 · see citing works
Self-citationKyei-Barffour, I., Addo, S. A., Aninagyei, E., Ghartey-Kwansah, G., & Acheampong, D. O. (2021) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2021.112282 · Cited by 12 · see citing works
A Review of Different Vaccines and Strategies to Combat COVID-19
Sabitha, S., Shobana, N., Prakash, P., Padmanaban, S., Sathiyasree, M., Saigeetha, S., Chakravarthi, S., Uthaman, S., Park, I., & Samrot, A. V. (2022) · Vaccines · doi:10.3390/vaccines10050737 · Cited by 19 · see citing works
ANCA-Associated Vasculitis May Result as a Complication to Both SARS-CoV-2 Infection and Vaccination
Christodoulou, M., Iatridi, F., Chalkidis, G., Λιούλιος, Γ., Nikolaidou, C. C., Badis, K., Fylaktou, A., Papagianni, A. A., & Stangou, M. J. (2022) · Life · doi:10.3390/life12071072 · Cited by 19 · see citing works
Recombinant Protein Vaccines against Human Betacoronaviruses: Strategies, Approaches and Progress
Kovalenko, A. O., Ryabchevskaya, E. M., Evtushenko, E. A., Nikitin, N. A., & Karpova, O. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021701 · Cited by 19 · see citing works
Prabakaran, R., Jemimah, S., Rawat, P., Sharma, D., & Gromiha, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-03436-z · Cited by 19 · see citing works
Thakur, N. N., Das, S., Kumar, S., Maurya, V. K., Dhama, K., Paweska, J. T., Abdel-Moneim, A. S., Jain, A., Tripathi, A. K., Puri, B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28060 · Cited by 18 · see citing works
Self-citationGringeri, M., Mosini, G., Battini, V., Cammarata, G. A. A. M., Guarnieri, G., Carnovale, C., Clementi, E., & Radice, S. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1917236 · Cited by 18 · see citing works
Saida, I. B., Maatouk, I., Toumi, R., Bouslama, E., Ismail, H. B., Salem, C. B., & Boussarsar, M. (2022) · Vaccines · doi:10.3390/vaccines10071012 · Cited by 16 · see citing works
Current clinical status of new COVID-19 vaccines and immunotherapy
Nagpal, D., Nagpal, S., Kaushik, D. K., & Kathuria, H. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22661-1 · Cited by 15 · see citing works
Soifer, M., Nguyen, N. V., Leite, R., Fernandes, J., & Kodati, S. (2022) · Vaccines · doi:10.3390/vaccines10111776 · Cited by 15 · see citing works
Challenges in Emerging Vaccines and Future Promising Candidates against SARS‐CoV‐2 Variants
Ghildiyal, T., Rai, N., Rawat, J. M., Singh, M., Anand, J., Pant, G., Kumar, G., & Shidiki, A. (2024) · Journal of Immunology Research · doi:10.1155/2024/9125398 · Cited by 15 · see citing works
A global survey in the developmental landscape of possible vaccination strategies for COVID-19
Gasmi, A., Srinath, S., Dadar, M., Pivina, L. M., Menzel, A., Benahmed, A. G., Chirumbolo, S., & Bjørklund, G. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108958 · Cited by 15 · see citing works
Siram, K., Lathrop, S. K., Abdelwahab, W., Tee, R. D., Davison, C. J., Partlow, H. A., Evans, J. T., & Burkhart, D. J. (2023) · Vaccines · doi:10.3390/vaccines12010021 · Cited by 14 · see citing works
Tulaihi, B. A., Alharbi, K. G., Alaboodi, T., Alkanhal, H., Alobaid, M. M., & Aldraimly, M. (2021) · Cureus · doi:10.7759/cureus.17768 · Cited by 13 · see citing works
Lu, C., Zhang, Y., Liu, X., Hou, F., Cai, R., Yu, Z., Liu, F., Yang, G., Ding, J., Xu, J., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105556 · Cited by 12 · see citing works
Javadi, M. M., Hosseinzadeh, M. T., Soleimani, N., & Rommasi, F. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105687 · Cited by 13 · see citing works
Liu, Y., Zhao, D., Wang, Y.-C., Chen, Z., Yang, L., Li, W., Gong, Y., Gan, C., Tang, J., Zhang, T., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011484 · Cited by 12 · see citing works
Noninfectious Uveitis Risk After COVID-19 Vaccination: A Nationwide Retrospective Cohort Study
Chang, M. S., Kim, H. R., Kim, S., Lee, C. S., Byeon, S. H., Kim, S. S., Lee, S. W., & Kim, Y. J. (2023) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2023.09.015 · Cited by 12 · see citing works
Wu, G., Du, J., Yu, C., Fu, Z., Zhang, X., Wang, L., & Wang, J. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.342349 · Cited by 10 · see citing works
Nechooshtan, R., Ehrlich, S., Vitikainen, M., Makovitzki, A., Dor, E., Marcus, H., Hefetz, I., Pitel, S., Wiebe, M., Huuskonen, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122119 · Cited by 10 · see citing works
Wei, J., Liu, C., He, X., Abbas, B., Chen, Q., Li, Z., & Feng, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010335 · Cited by 11 · see citing works
To do or not to do? Technological and social factors affecting vaccine coverage
Orlandi, L. B., Zardini, A., Rossignoli, C., & Ricciardi, F. (2021) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2021.121283 · Cited by 10 · see citing works
Eosinophil‐rich linear IgA bullous dermatosis induced by mRNA COVID ‐19 booster vaccine
Nahm, W. J., Juarez, M. C., Wu, J. H., & Kim, R. H. (2022) · Journal of Cutaneous Pathology · doi:10.1111/cup.14305 · Cited by 10 · see citing works
Emerging Cationic Nanovaccines
Carmona‐Ribeiro, A. M., & Pérez-Betancourt, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111362 · Cited by 8 · see citing works
Immunotherapy for neuroblastoma using mRNA vaccines
Ahmed, T. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100033 · Cited by 8 · see citing works
Recombinant vaccines: Current updates and future prospects
Kumar, V., Verma, A., Singh, R., Garg, P., Sharma, S. K., Singh, H. N., Mishra, S. K., & Kumar, S. (2024) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/apjtm.apjtm_854_23 · Cited by 8 · see citing works
Self-citationScope of SARS-CoV-2 variants, mutations, and vaccine technologies
Wambani, J., & OKOTH, P. K. (2022) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-022-00121-z · Cited by 8 · see citing works
Mobile On Demand COVID-19 Vaccine Production Units for Developing Countries
Fahr, S. R., Peña‐Benavides, S. A., Thiel, L., Sengoba, C., Karacasulu, K., Ihling, N., Sosa‐Hernández, J. E., Gilleskie, G. L., Woodley, J. M., Parra‐Saldívar, R., et al. (2022) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.2c01217 · Cited by 8 · see citing works
Boshra, M. S., Elgendy, M. O., Abdelaty, L. N., Tammam, M., Alanazi, A. S., Alzarea, A. I., Alsahali, S. M., & Sarhan, R. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192416803 · Cited by 8 · see citing works
An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen
Majidi, S., Kolyani, K. A., Akrami, M., & Dadar, M. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01409-5 · Cited by 7 · see citing works
McGrath, J., Kenny, C., Nielsen, C. S., Domegan, L. M., Walsh, C., Rooney, P., Walsh, S., Conlon, N. P., Brady, G., Ibrahim, A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1078022 · Cited by 7 · see citing works
Microencapsulation of Probiotics and Its Application as Co-Delivery Systems: Review of Literature
Kiprono, S. J., Wambani, J., Langat, V., Rono, J., & Yang, G. (2024) · ES Food & Agroforestry · doi:10.30919/esfaf1106 · Cited by 8 · see citing works
Homma, T., Nagata, N., Hashimoto, M., Iwata‐Yoshikawa, N., Seki, N. M., Shiwa-Sudo, N., Ainai, A., Dohi, K., Nikaido, E., Mukai, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25418-5 · Cited by 6 · see citing works
Wang, Y., Cheng, S.-T., Shen, C., Huang, S.-W., & Cheng, C. (2023) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2023.12.4.337 · Cited by 5 · see citing works
Sinovac vaccination and the course of COVID-19 disease in hospitalized patients in Turkey
Delen, L. A., & Örtekus, M. (2022) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2022.147 · Cited by 5 · see citing works
McGrath, J., O’Doherty, L., Conlon, N. P., Dunne, J., Brady, G., Ibrahim, A., McCormack, W. J., Walsh, C., Domegan, L. M., Walsh, S., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1245464 · Cited by 4 · see citing works
Feng, G., Wang, Z., He, P., Lan, Q.-Y., Ni, L., Yang, Y., Wang, C.-F., Cui, T.-T., Huang, L., Yan, Y.-Q., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2262635 · Cited by 4 · see citing works
Sequelas da Covid-19 e o papel da fisioterapia na reabilitação do paciente
Costa, C. S., Almeida, V. A. L., Oliveira, I. G. B., Oliveira, J. D. C. N. D., Bezerra, E. A. G., Lopes, M. C. S., Pereira, W. V. S., Barbosa, P. G. P., Barbosa, R. D. L., & Júnior, M. A. B. (2022) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e10052.2022 · Cited by 3 · see citing works
Liu, J., Li, Y., Wang, M., & Yang, J. (2024) · World Journal of Virology · doi:10.5501/wjv.v13.i2.91286 · Cited by 3 · see citing works
A review of SARS-CoV-2 virology, vaccines, variants and their impact on the COVID-19 pandemic
Hirahata, T., Quraish, R. U., Quraish, A. U., & Quraish, S. U. (2024) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000393 · Cited by 4 · see citing works
Addala, S., Vissapragada, M., Aggunna, M., Mukala, N., Lanka, M., Gampa, S., Sodasani, M., Chintalapati, J., Kamidi, A., Veeranna, R. P., et al. (2022) · Vaccines · doi:10.3390/vaccines10060841 · Cited by 3 · see citing works
COVID-19 Vaccines - Current State and Perspectives
Abdurakhmonov, I. Y. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101006 · Cited by 2 · see citing works
Zhou, Y.-F., Nie, J., Shi, C., Ning, K., Cao, Y., Xie, Y., Xiang, H., & Xie, Q. (2022) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2205.05023 · Cited by 3 · see citing works
Aripov, T., Wikler, D. I., Asadov, D. A., Tulekov, Z., Murzabekova, T., & Münir, K. (2022) · BMC Medical Ethics · doi:10.1186/s12910-022-00764-1 · Cited by 2 · see citing works
Bernauer, H. S., Maier, J. M., Bannert, N., & Ivanusic, D. (2024) · Biology Methods and Protocols · doi:10.1093/biomethods/bpae001 · Cited by 2 · see citing works
What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?
Kayali, F., Leung, M. S. T., Wong, W., Morgan, K., & Harky, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2057795 · Cited by 2 · see citing works
Effectiveness and Possible Side effects of the Covishield Vaccine in Preventing Covid-19
Tiwari, P., Tiwari, P., & Patel, P. (2025) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2025.00029 · Cited by 1 · see citing works
Previous and potential mutations of Sars-cov-2 receptors and their interaction with known inhibitors
Oranu, E. C., Ijeawele, A., Egbuna, R. N., Ezeonyi, E. I., Okolo, C. C., & Uzochukwu, I. C. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.24.3.0374 · Cited by 1 · see citing works
COVID-19 Vaccines: An Account of Need and Efficacy vs Safety and Challenges
Nag, A., Kalra, A., Sharma, H., Shringi, H., & Kumar, A. (2021) · LS International Journal of Life Sciences · doi:10.5958/2319-1198.2021.00010.5 · Cited by 1 · see citing works
Sharma, A., Noor, R., & Khan, S. (2022) · Asian Pacific Journal of Health Sciences · doi:10.21276/apjhs.2022.9.1.43 · Cited by 1 · see citing works
Bilateral optic neuritis and myocarditis after the first dose of COVID-19 vaccine
Abusamra, K., Kini, T. A., Sudhakar, P., & Ryan, S. (2022) · Neuroimmunology Reports · doi:10.1016/j.nerep.2022.100139 · Cited by 1 · see citing works
COVID-19 vaccines and homoeopathy – An integrative review
Gilla, D., Sreelakshmy, S. R., & Kumar, B. R. (2022) · Indian Journal of Research in Homoeopathy · doi:10.53945/2320-7094.1022 · Cited by 1 · see citing works
What Pausing the AI Arms Race is and isn't: the Right Side of History or Wishful Thinking
Blumenthal, R. L. (2023) · ACM SIGCAS Computers and Society · doi:10.1145/3625671.3625678 · Cited by 1 · see citing works
Brumeanu, T., Vir, P., Karim, A. F., Kar, S., Benetiene, D., Lok, M., Greenhouse, J. J., Putman-Taylor, T., Kitajewski, C., Chung, K. K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-225156/v1 · Cited by 1 · see citing works
Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19
Sharma, M., Singh, T. U., Lingaraju, M. C., & Parida, S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96899
An overview of COVID-19 vaccine candidates
Kang, J., Peng, S., Zhang, W., & Zuo, Y. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202129203060
COVID-19: Vaccines on Their Marks
Jagtiani, E., & Vithlani, D. (2021) · The Bombay Technologist · doi:10.36664/bt/2021/v68i1/162888
Vaccine Race for COVID-19 Battle
Khanal, D. P. (2021) · Journal of Manmohan Memorial Institute of Health Sciences · doi:10.3126/jmmihs.v7i1.43144
Leucocytoclastic Vasculitis Following Coronavirus Vaccine: A Case Report
Ochi, M. R. E., Bahadi, N., Zaizaa, M., Hallab, I., Allaoui, M., Essaoudi, A., Ktaibi, A. E., Sekkach, Y., Damiri, A., Chahdi, H., et al. (2022) · Saudi Journal of Medical and Pharmaceutical Sciences · doi:10.36348/sjmps.2022.v08i02.007
Velasco-Muso, M. V., Velasco-Basantes, M. M., Herrera-Méndez, A. M., & Alfonso-González, I. (2022) · Revista Arbitrada Interdisciplinaria de Ciencias de la Salud Salud y Vida · doi:10.35381/s.v.v6i1.1714
The efficacy and safety of COVID-19 vaccine A protocol of systematic review and meta-analysis
Xue, X., Deng, Z., Li, N., Zhou, L., Wang, N., Xu, F., & Wang, X. (2021) · doi:10.37766/inplasy2021.3.0048
Odetola, F. O. (2022) · Academic Emergency Medicine · doi:10.1111/acem.14548
Analyzing Toxicology Reports of the COVID-19 Vaccine
Lingala, E., Appavu, R., & Kethar, J. (2021) · Journal of Student Research · doi:10.47611/jsrhs.v10i4.1996
Efectividad de las vacunas COVID-19
Castañeda-Rodriguez, K. D. P., Gamboa-Cruzado, J., Montero, J. S. N., Villavicencio, L. I., & Zavala-Gutierrez, A. A. (2022) · Boletín de Malariología y Salud Ambiental · doi:10.52808/bmsa.7e6.624.018
da Silva, B. S., Sousa, F. V. V., Leite, L. A. R., Marinho, D. F., Ribeiro, A. P. L., de Sousa, E. S., dos Reis, J. M. F., da Silva, L. M. S., Vinholte, P. A. D. C., & Paiva, C. E. A. (2022) · Research Society and Development · doi:10.33448/rsd-v11i12.34545
Transmission and intervention dynamics of SARS-CoV-2
Korsah, M. A., Acquah, C., & Danquah, M. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91814-5.00009-x
ZF2001, A Protein Subunit Vaccines against SARS-CoV-2
Chen, F., & Gao, Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109170
Research progress of recombinant novel coronavirus protein vaccine
Hokwan, O., & Zhang, X. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v40i.6523
Novel Formulation Approaches for Treatment of Ebola Virus
Bhattacharya, S., Singh, S., Chakraborty, S., Prajapati, B. G., Chougule, M. B., & Patel, J. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-20537-8_7
Ghanem, H., Ghanem, S., & Almutawa, E. (2023) · Recent Patents on Biotechnology · doi:10.2174/1872208317666230612141930
Covid-19 vaccines and their adequacy prospects in Pakistani population; A comparative review
Awais, M. (2023) · Pure and Applied Biology · doi:10.19045/bspab.2023.120129
Purwanto, G. C. L., Damai, F. I., Agustiyanti, D. F., Wisnuwardhani, P. H., Fathurahman, A. T., Rubiyana, Y., Ramadani, R. D., Sidqi, M. K. L., Prasetyaningrum, P. W., Septisetyani, E. P., et al. (2023) · Indonesian Journal of Biotechnology · doi:10.22146/ijbiotech.82159
Efficacy of Natural Products against Zoonotic Disorders
(2023) · International Journal of Agriculture and Biosciences · doi:10.47278/book.zoon/2023.041
REVIEW: CHEMICAL BONDS IN MOLECULAR AGGREGATION – FROM DRINKING WATER TO NANOCOMPOSITES
Senna, M. (2024) · Citi Science · doi:10.60167/csj/v4i1.2024.02
Yeast-Produced S1 Recombinant Protein of SARS-CoV-2
Majidi, S., Aghaeipour, K. H., Kiasari, B. A., Akrami, M., Mohammadi, A., Najafi, H., & Mousavi, F. (2022) · Bulletin de la Banque nationale de Perse. · doi:10.61186/vacres.9.2.37
Exploring the promise of COVID-19 vaccines: A review of preclinical studies
Adhikary, S., Buttar, H. S., Tuli, H. S., & Kaur, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00052-4
TBHEB 2024-2 Vol 81 Full Printed Journal
ERCÖMERT, U. (2024) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2024.17999
COVID-19 vaccine hesitancy in Türkiye: An infodemiological study
Avcı, K. (2024) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2024.34079
Novel Design for Multi-Epitope Vaccines of COVID-19 and Critical In silico Assessment Steps
Lan, T., Su, S., Ping, P., & Li, J. (2024) · Current Bioinformatics · doi:10.2174/0115748936303461240827061629
- Authors
- Yadav, T., Srivastava, N., Mishra, G., Dhama, K., Kumar, S., Puri, B., & Saxena, S. K.
- Affiliations
- Department of Zoology, Jawaharlal Nehru Smriti Government Post Graduate College, Shujalpur, India
- Department of Biotechnology, Meerut Institute of Engineering and Technology, Meerut, India
- Indian Veterinary Research Institute (IN)
- King George's Medical University (IN)
- Corresponding author
- Saxena, Shailendra K
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2020-11-24
- Volume
- 16
- Issue
- 12
- Pages
- 2905-2912
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC7711739
- OpenAlex
- W3110025561
- Cited by
- 105
- References
- 41
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 14 · 2023: 20 · 2022: 40 · 2021: 22 · 2020: 2
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- CCRH
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- COVID-19 vaccines, SARS-CoV-2, recombinant vaccine, spike protein, vaccine design, vaccine safety, vaccine efficacy, nucleic acid vaccines, inactivated vaccine
- MeSH terms
- COVID-19, COVID-19 Vaccines, Genetic Vectors, Humans, Vaccines, Synthetic, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
